Journal
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
Volume 38, Issue 1, Pages 86-93Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PAS.0b013e3182a43996
Keywords
SOX11; mantle cell lymphoma; monoclonal antibody; qRT-PCR
Funding
- Swiss National Science Foundation
- Swiss Cancer League
- Fondo de Investigacion Sanitaria [PI11/00907]
- Red Tematica de Investigacion Cooperativa de Cancer (RTICC) [RD12/0036/0004]
- FEDER
- CICYT SAF [08/SAF 2008-03630]
- Instituto de Salud Carlos III [RD12/0036/0023]
Ask authors/readers for more resources
The diagnosis of mantle cell lymphoma (MCL) can be difficult, especially when no t(11; 14) translocation and cyclin D1 overexpression can be detected. In such cases, the transcription factor SOX11 represents an important diagnostic marker, as it is expressed in most MCLs and, in particular, in all cyclin D1-negative MCLs reported so far. A reliable anti-SOX11 antibody is therefore a very useful tool for routine diagnosis. Here, we characterize the new monoclonal anti-SOX11 antibodies, suitable for Western blot assay and immunohistochemistry (IHC) on formalin-fixed paraffin-embedded tissue; we tested them on a large series of primary lymphoid tumors and compared these results with those of other routinely used antibodies. Moreover, we show that IHC results depend on transcription levels of SOX11, which suggests that posttranscriptional and post-translational modifications do not significantly affect cutoff levels for IHC detection of SOX11.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available